BioCentury | Feb 6, 2019
Distillery Therapeutics

Neurology

...other methods for promoting GDNF secretion in the brains of epilepsy models. uniQure N.V. has AAV2-GDNF...
BioCentury | Feb 2, 2018
Product Development

AA Viral meme

...Dopa decarboxylase (DDC; AADC) Intracerebral infusion 2.371 x 1011 vg Ph II UniQure N.V. (NASDAQ:QURE) AAV2-GDNF...
BioCentury | Nov 18, 2016
Company News

uniQure restructuring news

...of €40.4 million ($44.9 million). uniQure N.V. (NASDAQ:QURE), Amsterdam, the Netherlands Business: Gene/Cell therapy, Pharmaceuticals Chris Lieu AAV-S100A1 AAV2-GDNF AMT-060 AMT-110 AMT-130 Bristol-Myers...
BioCentury | Nov 15, 2016
Company News

uniQure paring down gene therapy portfolio

...a smaller R&D unit in Amsterdam, the Netherlands. uniQure shed $0.57 to $7.73 on Tuesday. Chris Lieu AAV-S100A1 AAV2-GDNF AMT-060 AMT-110 AMT-130 Bristol-Myers...
BioCentury | Mar 9, 2015
Emerging Company Profile

AAVs for the CNS

...therapy that delivers a different gene to treat PD that is in Phase I testing. AAV2-GDNF...
BioCentury | Sep 2, 2013
Clinical News

AAV2-GDNF: Phase I started

...of Neurological Disorders and Stroke (NINDS) began an open-label, dose-escalation Phase I trial to evaluate AAV2-GDNF...
...in about 24 PD patients. Last year, Amsterdam Molecular Therapeutics N.V. dissolved its assets, including AAV2-GDNF...
...Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). uniQure B.V. , Amsterdam, the Netherlands Product: AAV2-GDNF (formerly AMT-090...
BioCentury | Jul 2, 2012
Clinical News

AAV2-GDNF: Phase I start

...of Neurological Disorders and Stroke (NINDS) will begin an open-label Phase I trial to evaluate AAV2-GDNF...
...about 24 PD patients. Earlier this year, Amsterdam Molecular Therapeutics N.V. dissolved its assets, including AAV2-GDNF...
...Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). uniQure B.V. , Amsterdam, the Netherlands Product: AAV2-GDNF (formerly AMT-090...
BioCentury | Feb 20, 2012
Company News

Amsterdam Molecular, uniQure deal

...continue to invest in Amsterdam's Phase I/II compound AMT-060 for hemophilia B, and preclinical compounds: AMT-090...
...acute intermittent porphyria. AMT-060 is an adeno-associated viral (AAV) vector encoding the Factor IX gene. AMT-090...
BioCentury | Feb 18, 2012
Company News

Amsterdam Molecular to transfer assets, delist

...continue to develop Amsterdam's Phase I/II gene therapy AMT-060 for hemophilia B, and preclinical compounds AMT-090...
BioCentury | Jan 2, 2012
Finance

Small-fry squashed

...A) Focusing on three gene therapy programs: AMT-060 in Phase I/II for hemophilia B; and AMT-090...
Items per page:
1 - 10 of 14